openPR Logo
Press release

Meningococcal Vaccine Market is Projected to Grow at a 10.3% CAGR, Reaching US$ 10,788.0 Million by 2034 | Fact.MR Report

04-03-2025 09:40 AM CET | Health & Medicine

Press release from: Fact.MR

Meningococcal Vaccine Market

Meningococcal Vaccine Market

The meningococcal vaccine market across the globe is anticipated to grow at a CAGR of 10.3% during the period between 2024 and 2034. The market is anticipated to be worth US$ 4,049.1 million in 2024. Meningococcal vaccine sales are anticipated to grow to US$ 10,788.0 million by 2034.

The market is driven by the high incidence of meningococcal diseases, especially meningococcal meningitis, which are highly contagious in humans or groups. The increase in cases of these diseases is driving demand for meningococcal vaccination. Increasing focus on preventive care is also generating market demand.

For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9585

Country-wise Insights

The North American meningitis vaccine market is estimated to grow at a 11.1% CAGR until 2034. In 2024, the United States is expected to lead the North American meningococcal vaccine market with a 92.5% market share.

East Asia's meningococcal vaccine market is expected to grow at a 9.8% CAGR until 2034. In 2024, meningitis vaccines are expected to hold 59.1% of China's market.

The need for meningococcal vaccines will grow significantly in China, with a forecasted market value of US$ 173 million in 2024. Furthermore, the expected CAGR in the forecast period is 10.0%, which is quite high. This growth is anticipated to lead to a market value of US$ 451 million by 2034.

Category-wise Insights

The meningococcal conjugate vaccine (MCV4) segment is anticipated to contribute 41.6% market share in terms of product type in 2024. At the same time, the serogroup B meningococcal vaccine (MenB-FHpb/MenB-4C) segment is anticipated to capture 35.3% of the market, greatly improving the industry's source diversification and stability.

According to age, teenagers and young adults will account for a dominant 28.4% of the meningococcal vaccination market in 2024. Children between the ages of 2 to 12 years are expected to maintain 25.5% market share in 2024.

Competitive Landscape

The major players involved in the market for meningococcal vaccine are Incepta Pharmaceuticals Limited, Novartis International, GlaxoSmithKline plc, Merck, CSL, Baxter International, JN International Medical Corporation, Serum Institute of India, Biomed Pvt. Ltd, China National Biotec Group, Hualan Biological Engineering Inc., Walvax Biotechnology Co., Ltd., Zhifei, Pfizer Inc., GlaxoSmithKline plc., Sanofi SA, and Nuron Biotech.

The international meningococcal vaccination market is expanding rapidly and is a highly competitive industry where numerous firms are competing for market share and a strong foundation. Various factors such as price strategies, advertising campaigns, research and development, and innovative product development fuel market competition.

Owing to the high degree of fragmentation of the meningitis vaccine market and competition among the firms for market share, there is a higher focus on strategic decision-making and competitive forces. Players are investing heavily in research and development to develop new, more effective vaccines to gain a competitive edge.

To enhance the effectiveness of operation and maximize market penetration, partnerships, joint ventures, and other strategic collaborations are also being established. Product launches and other promotional campaigns are also utilized by companies to boost meningitis vaccine sales and gain a competitive edge.

Recent Developments:

In December 2023, Pfizer received the FDA approval of Penbraya, the first pentavalent meningococcal disease vaccine for people aged 10-25 years, which delivers robust protection against severe and life-threatening infection in adolescents and young adults.
The Serum Institute of India Private Limited developed MenFive, the world's first conjugate vaccine pre-qualified by the World Health Organization to guard against Africa's five leading causes of meningococcal meningitis, in July 2023.

Browse Full Report: https://www.factmr.com/report/meningococcal-vaccine-market

Segmentation of the Meningococcal Vaccine Market

By Product type :
Meningococcal Polysaccharide Vaccine (MPSV4)
Meningococcal Conjugate Vaccine (MCV4)
Serogroup B Meningococcal Vaccine (MenB-FHpb/MenB-4C)
By Age Group :
Infants (0-24 months)
Children (2-12 years)
Adolescents and young adults
Adults
By Distribution Channels :
Institutional Sales
Retail Sales
By Region :
North America
Europe
East Asia
East Asia
South Asia & Oceania
Middle East & Africa

Check out More Related Studies Published by Fact.MR:

Medical Equipment Cooling Market
https://www.factmr.com/report/medical-equipment-cooling-market

Spinal Trauma Devices Market
https://www.factmr.com/report/spinal-trauma-devices-market

Anticoagulant Reversal Drugs Market
https://www.factmr.com/report/4338/anticoagulant-reversal-drugs-market

Orthopedic Medical Imaging Systems Market
https://www.factmr.com/report/orthopedic-medical-imaging-systems-market

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Meningococcal Vaccine Market is Projected to Grow at a 10.3% CAGR, Reaching US$ 10,788.0 Million by 2034 | Fact.MR Report here

News-ID: 3953202 • Views:

More Releases from Fact.MR

Fine Blanking Tools Market Projected to Reach USD 1.43 Billion by 2035 | U.S. CAGR at a 5.3%
Fine Blanking Tools Market Projected to Reach USD 1.43 Billion by 2035 | U.S. CA …
The global Fine Blanking Tools Market is set for steady growth over the next decade, driven by rising demand for high-precision components, ongoing industrial automation, and surging requirements from automotive, electronics, and aerospace sectors. According to a recent forecast, the market is expected to grow from approximately USD 948.1 million in 2025 to USD 1,430.6 million by 2035, at a compound annual growth rate (CAGR) of about 4.2 % between
Benzodiazepine Drugs Market is Expanding USD 5.4 billion by 2035 | Pfizer Inc.; Akorn Inc; Hikma; Hameln Pharmaceutical; Accord; Others.
10-08-2025 | Health & Medicine
Fact.MR
Benzodiazepine Drugs Market is Expanding USD 5.4 billion by 2035 | Pfizer Inc.; …
The global benzodiazepine drugs market is projected to expand in the coming decade, driven by growing incidence of anxiety, insomnia, alcohol-withdrawal disorders, and advances in pharmaceutical formulations. According to a recent Fact.MR report, the market was valued at approximately USD 2.35 billion in 2022, and is expected to grow at a compound annual growth rate (CAGR) of 2.8% to reach USD 3.1 billion by 2032. Market Drivers & Outlook The demand for
Ultrasound Systems Market to Surge to Nearly USD 20 Billion by 2035, Led by Advances in 2D, Cart-Based Systems & AI-Enabled Portability
10-08-2025 | Health & Medicine
Fact.MR
Ultrasound Systems Market to Surge to Nearly USD 20 Billion by 2035, Led by Adva …
The global Ultrasound Systems Market is on a strong growth trajectory, projected to rise from USD 10.8 billion in 2025 to approximately USD 19.7 billion by 2035, expanding at a CAGR of 6.2% during the forecast period. This growth is fueled by the rising demand for non-invasive diagnostic imaging, the increasing prevalence of chronic diseases, expanding healthcare infrastructure, and continuous technological innovations such as AI integration and portable imaging systems. Key
Surgical Staplers Market Is Forecasted To Reach USD 6.0 Billion In 2025 | Ethicon US LLC, Cardica Inc., Smith & Nephew Plc, CONMED Corporation., Purple Surgical Inc., Dextera Surgical Inc, and Others.
10-08-2025 | Health & Medicine
Fact.MR
Surgical Staplers Market Is Forecasted To Reach USD 6.0 Billion In 2025 | Ethico …
The global Surgical Staplers Market is forecast to show strong growth over the next decade, nearly doubling in value as demand surges for efficient, reliable wound closure in advanced surgical procedures. According to the latest Fact.MR Surgical Staplers Market Size & Share Forecast Outlook 2025-2035 report, the market is expected to grow from USD 6.0 billion in 2025 to USD 12.5 billion by 2035, at a compound annual growth rate

All 5 Releases


More Releases for Meningococcal

Impact Of Rising Healthcare Spending On Meningococcal Vaccines: An Emerging Driv …
The Meningococcal Vaccines Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Meningococcal Vaccines Market Size and Projected Growth Rate? The market size for meningococcal vaccines has seen rapid expansion in the past few years. The market is forecasted to increase from $3.89 billion
Meningococcal Vaccines Market: Combating Life-Threatening Infections
In recent years, the global Meningococcal Vaccines Market has witnessed a dynamic shift, influenced by changing consumer preferences, technological advancements, and a growing emphasis on sustainability. The Research report on Meningococcal Vaccines Market presents a complete judgment of the market through strategic insights on future trends, growth factors, supplier landscape, demand landscape, Y-o-Y growth rate, CAGR, pricing analysis. It also provides and a lot of business matrices including
Meningococcal Vaccines Market
Meningococcal Vaccines Market 2022 The Meningococcal Vaccines Market is expected to grow on an unabashed note in the next decade. With a worldwide shortage of healthcare staff, the healthcare IT solutions comprising web-based staffing platforms are doing the rounds. The future scenario won't be any different. These platforms would show the gaps, i.e. actual dearth of healthcare personnel like nurse's doctors, technicians, lab workers, and clinicians, which would help the entire
Meningococcal Vaccines Market Report Up to 2031
Visiongain has published a new report on Meningococcal Vaccines Market Report 2021-2031: Forecasts by Vaccine Type (Conjugate, Polysaccharide, Others), by End-user (Paediatric, Adult, Traveler), by Brand (Bexsero, Menactra, Menveo, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios. Download Exclusive Sample of Report @ https://www.visiongain.com/report/meningococcal-vaccines-market-2021/#download_sampe_div Rise in prevalence of meningitis, increasing initiatives by government and regulatory authorities coupled strong funding support from non-profit organizations
Global Meningococcal Vaccines Market Research Report
This report studies the global Meningococcal Vaccines market status and forecast, categorizes the global Meningococcal Vaccines market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report GlaxoSmithKline JN-International Medical Novartis International Sanofi Pfizer Baxter International Geographically, this report studies the top producers and
Meningococcal Vaccines Market Growth by 2028 | GlaxoSmithKline, Polysaccharide M …
Partnerships between the private sector and public institutions have been the chief agenda of global public health initiatives. The last few years have witnessed an increase in several private-public partnerships specifically focussing on vaccine provision in developing countries. Partnerships like the International Coordinating Group on Vaccine Provision for Epidemic Meningitis Control (ICG) help magnify the vaccine outreach to remote areas of the world with the maximum need. The governments of